BookAndreas Engert, Anas Younes, editors.
Summary: This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.
Contents:
Intro
Preface
Contents
Part I: Epidemiology and Pathogenesis
1: Epidemiology of Hodgkin Lymphoma
1.1 Introduction
1.2 Definition and Histological Classification (WHO)
1.3 Hodgkin Lymphoma Occurrence
1.3.1 Overall Incidence
1.3.2 Age-Specific Incidence Patterns Vary Geographically
1.3.2.1 Historical Patterns
1.3.2.2 Modern Age-Specific Incidence Patterns
1.3.2.3 Age-Specific Incidence Patterns for Hodgkin Lymphoma Subtypes
1.3.3 Incidence Trends
1.3.4 Classifications for Epidemiological Studies: Multi-disease Models 1.3.5 Classifications by Age at Diagnosis, Histology and Tumour Epstein-Barr Virus Status
1.3.6 Overlap Between Epidemiological Classifications of Hodgkin Lymphoma
1.4 Familial Accumulation of Hodgkin Lymphoma: Genetic Predisposition
1.4.1 Genetic Studies: Genome-Wide Association Studies
1.4.1.1 Hodgkin Lymphoma Subtype-Specific Associations in Genetic Analyses
1.5 Risk Factors
1.5.1 Prevailing Hypotheses in Hodgkin Lymphoma Epidemiology
1.5.1.1 Childhood Socio- Economic Environment
1.5.2 Anthropometry
1.5.3 Medical History
1.5.3.1 Infections Epstein-Barr Virus Infection: Infectious Mononucleosis
Epstein-Barr Virus Infection: Serological Evidence
Epstein-Barr Virus Infection: Variation in Tumour Prevalence
A Four-Disease Model for Hodgkin Lymphoma
Other Childhood Infections
1.5.3.2 Primary and Secondary Immune Deficiencies
1.5.3.3 Autoimmune and Allergic Disorders
Autoimmune and Allergic/Atopic Diseases
1.5.3.4 Medications
1.5.4 Environmental Exposures
1.5.4.1 Ultraviolet Light
1.5.4.2 Tobacco
1.5.4.3 Alcohol
1.6 Conclusion
References 2: The Role of Viruses in the Genesis of Hodgkin Lymphoma
2.1 Introduction
2.2 Hodgkin Lymphoma and Epstein-Barr Virus
2.2.1 Epstein-Barr Virus and the Pathogenesis of Hodgkin Lymphoma
2.2.2 Risk Factors for Epstein-Barr Virus-Associated Hodgkin Lymphoma
2.2.3 Epstein-Barr Virus and Hodgkin Lymphoma: A Causative Association?
2.2.4 Epstein-Barr Virus and the Clinicopathological Features of Hodgkin Lymphoma
2.3 Epstein-Barr Virus-Negative Hodgkin Lymphoma Cases
2.3.1 Hodgkin Lymphoma and Herpesviruses Other Than Epstein-Barr Virus 2.3.2 Polyomaviruses and Hodgkin Lymphoma
2.3.3 Measles Virus and Hodgkin Lymphoma
2.3.4 The Virome, Anelloviruses, and Hodgkin Lymphoma
2.4 Conclusions
References
3: Pathology and Molecular Pathology of Hodgkin Lymphoma
3.1 Subclassification and Pathology
3.1.1 Nodular Lymphocyte-Predominant Hodgkin Lymphoma
3.1.2 Classical Hodgkin Lymphoma: The HRS Cells
3.1.2.1 Nodular Sclerosis Classical Hodgkin Lymphoma
3.1.2.2 Mixed Cellularity Classical Hodgkin Lymphoma
3.1.2.3 Lymphocyte-Depleted Classical Hodgkin Lymphoma
3.1.2.4 Lymphocyte-Rich Classical Hodgkin Lymphoma